IMGN Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.07%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

ImmunoGen Insider Trading History Chart

This chart shows the insider buying and selling history at ImmunoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

ImmunoGen Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 02/26/2024 01:00 AM ET

This chart shows the closing price history over time for IMGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for ImmunoGen (NASDAQ:IMGN)

90.50% of ImmunoGen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
ImmunoGen logo
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
Read More on ImmunoGen

Today's Range

Now: N/A

50 Day Range

MA: $31.23
Low: $31.23
High: $31.23

52 Week Range

Now: N/A

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Who are the company insiders with the largest holdings of ImmunoGen?

ImmunoGen's top insider shareholders include:
  1. Mark J Enyedy (CEO)
  2. Stacy Ann Coen (SVP)
  3. Renee Lentini (Insider)
  4. Renee Lentini (VP)
  5. Theresa Wingrove (SVP)
  6. Kristine Peterson (Director)
Learn More about top insider investors at ImmunoGen.